π¬ Barrow launches ibogaine study for brain injuries
Barrow Neurological Institute is starting a Phase 1/2 clinical trial to test ibogaine for neurological disorders like TBI. This groundbreaking study involves a multidisciplinary team at Barrow and Arizona State University. It aims to enroll 40 participants with chronic TBI symptoms, with the first enrollment targeted for 2027. The trial will compare ibogaine against a placebo to assess its effectiveness on symptoms and quality of life. Researchers hope this research will advance understanding of brain function beyond traditional neurology.